Circulating tumor cells (CTCs) are an early warning sign of cancer
Tumors begin to grow up as many as 5 to 10 years before they are detected. Circulating tumor DNA (ctDNA) and Circulating Tumor Cells (CTCs) are well-established cancer markers. ctDNA has demonstrated low sensitivity in early-stage cancer, while CTCs enter the bloodstream from the earliest days of tumor development.
Rarecells’ proprietary ISET® (Isolation by Size of Tumor cells) device is a certified CE-Mark In Vitro Diagnostic (CE-IVD) platform with CE-validated unparalleled ability to extract down to a single cancer cell from among 50 billion blood cells in a 10 ml blood sample.
The new ISET® process enables optimized extraction of both CTC-DNA and ctDNA from a single stabilized blood sample collected in standard Streck® tubes.
Clinical data from the ongoing BioMolCTC study – in collaboration with the Agostino Gemelli University in Rome, Italy – were presented in an ePoster at the 2025 World Conference on Lung Cancer in Barcelona, Spain.
Early findings demonstrate that ISET® CTC-DNA provides greater sensitivity and improved detection of tumor heterogeneity compared with ctDNA alone in patients with early-stage lung cancer.
Moreover, the combined analysis of circulating tumor DNA (ctDNA) and ISET® CTC-DNA delivered the highest sensitivity and the most comprehensive genomic profile of the tumor.
Next-generation ISET® CTC-DNA shows superior sensitivity and tumor heterogeneity detection than ctDNA.
A strong base of published evidence
ISET®’s groundbreaking sensitivity and specificity have been established through 110+ high-level, peer-reviewed and independent scientific publications. Studies demonstrated the efficacy and utility of tests using ISET®-collected cells in early detection of cancer, cancer prognosis, and non-invasive theranostics.
0
TYPES OF CANCER
0
+
CLINICAL STUDIES
0
K+
PATIENTS STUDIED